203 related articles for article (PubMed ID: 36279850)
1. Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review.
Hropot T; Battelino T; Dovc K
Horm Res Paediatr; 2023; 96(6):620-630. PubMed ID: 36279850
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
[TBL] [Abstract][Full Text] [Related]
4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Yang Y; Pan H; Wang B; Chen S; Zhu H
Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981
[TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Li K; Xu G
J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
[TBL] [Abstract][Full Text] [Related]
8. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Taylor SI; Blau JE; Rother KI; Beitelshees AL
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):949-958. PubMed ID: 31585721
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
[TBL] [Abstract][Full Text] [Related]
14. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
15. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
17. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
[TBL] [Abstract][Full Text] [Related]
19. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]